Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Operating Leases (2020 - 2021)

Alaunos Therapeutics (TCRT) has disclosed Operating Leases for 2 consecutive years, with $4.7 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Operating Leases changed N/A year-over-year to $4.7 million, compared with a TTM value of $4.7 million through Sep 2021, changed N/A, and an annual FY2020 reading of $4.0 million, changed N/A over the prior year.
  • Operating Leases was $4.7 million for Q3 2021 at Alaunos Therapeutics, down from $4.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $4.9 million in Q2 2021 and bottomed at $4.0 million in Q4 2020.